Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

s in patients within the first 12 days following initiation of treatment but also significantly reduced persistent diarrhea, disease recurrence or death through day 40 of the study."

The analysis was independently funded by the NIHR Biomedical Research Centre, Oxford, a research partnership between the Oxford Radcliffe Hospitals and the University of Oxford.

Study Methods

The analysis was performed using data from two prospective, randomized, double-blinded, non-inferiority Phase 3 studies evaluating DIFICID and oral vancomycin in the treatment of CDAD in adults 18 years of age or older. A non-inferiority design was utilized to demonstrate the efficacy of DIFICID (200 mg orally twice daily for 10 days) compared to vancomycin (125 mg orally four times daily for 10 days) in adults with CDAD. The studies enrolled a total of 1,164 adults with confirmed CDAD. The primary objective of both studies was to show that a 10-day course of DIFICID was as effective as oral vancomycin in achieving a clinical cure at the end of therapy. Clinical cure was defined as resolution of diarrhea (no more than 3 unformed stools for 2 consecutive days) maintained for the duration of therapy with no further requirement for therapy assessed two days after the end of the 10 day treatment. Subjects meeting the criteria for clinical cure were followed for 28 days after the end of treatment (36-40 days after randomization) and assessed for the additional efficacy endpoints of recurrence and global cure. Recurrence was defined by the reappearance of more than 3 unformed stools in any 24-hour period with C. difficile toxin A or B or both detected and a need for retreatment.  Global cure was defined as clinical cure without recurrence.  

To compile the results, researchers conducted a post-hoc exploratory analysis to determine the time-to-event for a composite endpoint of persistent diarrhea, disease recurrence or death of the combined intent-to-tre
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Boehringer Ingelheim will contribute to advancing ... American Thoracic Society International Conference (ATS 2013) in ... – 22. Data will highlight research ... of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® ... compounds for asthma, idiopathic pulmonary fibrosis (IPF) and ...
(Date:5/17/2013)... 2013 Oramed Pharmaceuticals Inc. (NASDAQCM: ... delivery systems, announced today that the United States Food ... New Drug application(IND) for ORMD-0801, its oral insulin capsule. ... FDA clearance to proceed," stated Nadav Kidron ... a major milestone for Oramed and we look forward ...
(Date:5/16/2013)... CHICAGO, Ill. and MECHELEN, Belgium ... (Euronext: GLPG) and AbbVie (NYSE: ABBV ) ... collaboration to include Crohn,s disease.  Galapagos will fund and ... is designed to facilitate rapid progression into Phase 3.  ... 2015, AbbVie will pay Galapagos $50 million.  The terms ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... couples to create page on Pinktimeline.com to receive £50 ... have launched a fundraising resource on their website, http://www.pinktimeline.com ... for associated costs. Couples can create a private fundraising page ... raise funds for specialty consultations, fertility treatments or even to ...
... 25, 2011 INNOPHARMA LLC announced today FDA approval of ... generic equivalent of Zyprexa® injection). As the developer ... with Sandoz Inc., pursuant to which Sandoz will sell, market ... About INNOPHARMA: INNOPHARMA is ...
Cached Medicine Technology:First Response Launches IVF Fundraising Resource for Those Trying for a Baby 2First Response Launches IVF Fundraising Resource for Those Trying for a Baby 3
(Date:5/18/2013)... (May 18, 2013) A ground-breaking advance in ... according to research presented today at Digestive Disease ... minimal withdrawal time for colonoscopies and exploring safer ... colonoscopy, doctors use a device called a colonoscope ... colorectal cancer allows a doctor to look for ...
(Date:5/18/2013)... York (PRWEB) May 18, 2013 ... mesh products continue to move forward in a consolidated ... Bernstein Liebhard LLP reports. According to a notice on ... the Ethicon pelvic mesh litigation will be held on ... complaints have been filed in the proceeding on behalf ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... DC (PRWEB) May 18, 2013 Family Magazine ... designation for excellence by Follow Media Consulting, Inc. in the ... signifies the continued commitment and dedication of the areas best ... , No one knows parenting better than Brenda Hyde, a ... is to help parents know about the vast resources available ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2
... -- Alcohol use by American teens has dropped to historic ... believe it,s a dangerous drug, according to an annual national ... and the University of Michigan. The nationally representative survey ... 400 public and private schools found a continuing trend of ...
... GURGAON, Delhi (NCR), India -- Vishwa Mohan Katoch, M.D., ... India: Future Directions" at the AACR International Conference on ... Therapy, Dec. 13-16, 2011, in Gurgaon, Delhi (NCR), India. ... India Department of Health Research and director-general of the ...
... cancers worldwide. Kaposi,s sarcoma herpesvirus (KSHV) is an etiological ... lymphoproliferative malignancies. KS is the most common cancer in ... cancer deaths in many subequatorial African countries as a ... of Biotechnology and Research Programs Unit (Genome-Scale Biology) at ...
... and the Management Sciences (INFORMS) today announced the award ... Medal to Dr. Don N. Kleinmuntz, President and co-founder ... web-based financial analytics and performance management software tools used ... their financial planning, budgeting, and reporting processes. , ...
... News) --,A new study finds that two out of ... hands. Researchers gave seven scenarios to 85 third-year ... asked them to identify which of the situations required ... correctly identified the five scenarios that required hand hygiene: ...
... conducted by researchers at Boston University School of Medicine ... house dust extract (HDE) causes pulmonary inflammation that aggravates ... PhD, professor of pathology, was published in the December ... and was selected by the editorial board as the ...
Cached Medicine News:Health News:Alcohol Use Down, Pot Use Up Among U.S. Teens 2Health News:KS-herpesvirus induces reprogramming of lymphatic endothelial cells to invasive mesenchymal cells 2Health News:INFORMS presents Ramsey Medal to health care financial analytics executive Don Kleinmuntz 2
... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...
... 23 gauge thin wall irrigation. 25 ... degree shaft 10 mm from tip ... mm behind aspiration tip. Side taper ... (18.1 inches) of silicone tubing (N5941 ...
... with five legs for extra stability. Adjustable ... vertical travel 6"). 2" ball bearing swivel ... retardant upholstery, available in black vinyl as ... Top of the range pneumatic stool with ...
Lacrimal Cannulas, 26 g. curved. Overall length 29 mm. 5/box....
Medicine Products: